ES2067744T3 - Aminas heterociclicas con actividad sobre el sistema nervioso central. - Google Patents

Aminas heterociclicas con actividad sobre el sistema nervioso central.

Info

Publication number
ES2067744T3
ES2067744T3 ES90908816T ES90908816T ES2067744T3 ES 2067744 T3 ES2067744 T3 ES 2067744T3 ES 90908816 T ES90908816 T ES 90908816T ES 90908816 T ES90908816 T ES 90908816T ES 2067744 T3 ES2067744 T3 ES 2067744T3
Authority
ES
Spain
Prior art keywords
nervous system
central nervous
activity
compounds
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90908816T
Other languages
English (en)
Inventor
Malcolm W Moon
Richard F Heier
Jeanette K Morris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Application granted granted Critical
Publication of ES2067744T3 publication Critical patent/ES2067744T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

COMPUESTOS CONTENIENDO NITROGENO TRICICLICO, CON ACTIVIDAD EN EL SISTEMA NERVIOSO CENTRAL DE FORMULA ESTRUCTURAL (I) Y SUS SALES FARMACEUTICAMENTE ACEPTABLES, DONDE R SUB 1, R SUB 2 Y R SUB 3 SON INDEPENDIENTEMENTE HIDROGENO, ALQUILO C SUB 1-6, ALQUENILO O ALQUINILO, CICLOALQUILO C SUB 3-10, O R SUB 1 Y R SUB 2 SE UNEN PARA FORMAR UNA AMINA CICLICA C SUB 3-7 QUE PUEDE CONTENER HETEROATOMOS ADICIONALES; X ES HIDROGENO, ALQUILO C SUB 1-6, HALOGENO, HIDROXI, ALCOXI, CIANO, CARBOXAMIDA, CARBOXILO, O CARBOALCOXILO; A ES SO SUB 2, N, CH, CH SUB 2, CHCH SUB 3, C = O, C = S, C-SCH SUB 3, C = NH, C-NH SUB 2, C-NHCH SUB 3, C-NHCOOCH SUB 3, O C-NHCN; B ES CH SUB 2, CH, C = O, N, NH O N-CH SUB 3; N ES 0 O 1; Y D ES CH, CH SUB 2, C = O, O, N, NH O N-CH SUB 3. ESTOS NUEVOS COMPUESTOS SON APROPIADOS PARA TRATAR LA ESQUIZOFRENIA, ENFERMEDAD DE PARKINSON, ANSIEDAD, DEPRESION O COMO COMPUESTOS PARA BAJAR LA PRESION SANGUINEA EN ANIMALES O RECEPTORES HUMANOS.
ES90908816T 1989-06-09 1990-05-15 Aminas heterociclicas con actividad sobre el sistema nervioso central. Expired - Lifetime ES2067744T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36437489A 1989-06-09 1989-06-09

Publications (1)

Publication Number Publication Date
ES2067744T3 true ES2067744T3 (es) 1995-04-01

Family

ID=23434241

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90908816T Expired - Lifetime ES2067744T3 (es) 1989-06-09 1990-05-15 Aminas heterociclicas con actividad sobre el sistema nervioso central.

Country Status (15)

Country Link
EP (1) EP0480939B1 (es)
JP (1) JP2955358B2 (es)
KR (1) KR0167346B1 (es)
AT (1) ATE117688T1 (es)
AU (1) AU626427B2 (es)
CA (1) CA2051697C (es)
DE (1) DE69016430T2 (es)
DK (1) DK0480939T3 (es)
ES (1) ES2067744T3 (es)
FI (2) FI96310C (es)
HK (1) HK65397A (es)
HU (2) HU210264B (es)
NO (1) NO301421B1 (es)
RU (1) RU2023712C1 (es)
WO (1) WO1990015058A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05117276A (ja) * 1991-10-23 1993-05-14 Sumitomo Pharmaceut Co Ltd 新規な３環性キノキサリンジオン誘導体
TW260660B (es) * 1993-04-22 1995-10-21 Sumitomo Pharma
DE4314593A1 (de) * 1993-04-28 1994-11-03 Schering Ag Pyrido(1,2,3-de)chinoxalinderivate, Verfahren zu deren Herstellung und ihre Verwendung von Arzneimitteln
ATE159943T1 (de) * 1993-07-27 1997-11-15 Upjohn Co Heterozyclische amine mit zns-wirksamkeit
FR2719843B1 (fr) * 1994-05-10 1996-06-07 Synthelabo Dérivés de 5,6-dihydro-4h-imidazo [2',1':2,3] imidazo-[4,5,1-ij] quinoléine et de 4,5-dihydroimidazo [1,2-a] pyrrolo-[1,2,3-cd] benzimidazole, leur préparation et leur application en thérapeutique.
EP0705834A1 (de) * 1994-07-27 1996-04-10 Ciba-Geigy Ag Azaaliphatisch Überbrückte Chinoxalin-2,3-dione
EP0705835A1 (de) * 1994-09-01 1996-04-10 Ciba-Geigy Ag Oxa- oder thiaaliphatisch überbrückte Chinoxalin-2,3-dione
ES2193255T3 (es) * 1995-08-10 2003-11-01 Bayer Cropscience Ag Halogenobencimidazoles y su empleo como microibicidas.
US6288075B1 (en) 1998-02-26 2001-09-11 Rhone-Poulenc Rorer S.A. Thiazolo[5,4,3-ij]quinolines, preparation and medicines containing the same
FR2760237B1 (fr) * 1997-02-28 1999-04-16 Rhone Poulenc Rorer Sa Thiazolobenzoheterocycles, leur preparation et les medicaments les contenant
US6197339B1 (en) * 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
US6455564B1 (en) * 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
AU767089B2 (en) * 1999-02-05 2003-10-30 Pharmacia & Upjohn Company Process to prepare (5R)-(methylamino)-5,6-dihydro-4H- imidazo(4,5,1-ij)-quinolin-2(1H)-one
US7074927B2 (en) 1999-05-13 2006-07-11 Pharmacia & Upjohn Company Heterocyclic amines having central nervous system activity
DE19954707A1 (de) * 1999-11-13 2001-05-17 Merck Patent Gmbh Imidazolverbindungen als Phosphodiesterase VII-Hemmer
GB0008939D0 (en) 2000-04-11 2000-05-31 Glaxo Group Ltd Process for preparing substituted benzimidazole compounds
NZ531171A (en) 2000-04-21 2005-03-24 Upjohn Co Cabergoline-type compounds for treating fibromyalgia and chronic fatigue syndrome
AR033520A1 (es) * 2000-04-27 2003-12-26 Upjohn Co (5r)-(metilamino) -5,6-dihidro-4h-imidazo[4,5,1-ij] quinolin-2(1h)-tiona
AU2001283393B2 (en) 2000-08-16 2005-09-22 Pharmacia & Upjohn Company Compounds for the treatment of addictive disorders
US6759405B2 (en) 2000-11-03 2004-07-06 Wyeth Cycloocta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
AR031202A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Ciclopenta(b) (1,4)diazepino(6,7,1-hi) indoles y derivados
US6858604B2 (en) 2000-11-03 2005-02-22 Wyeth Cyclohepta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
TWI312781B (en) 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200307682A (en) 2002-04-25 2003-12-16 Wyeth Corp 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200307540A (en) 2002-04-25 2003-12-16 Wyeth Corp [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents
MY136318A (en) * 2002-07-25 2008-09-30 Pharmacia Corp Sustained-release tablet composition
US20050079217A1 (en) * 2002-07-25 2005-04-14 Ganorkar Loksidh D. Sustained-release tablet composition comprising a dopamine receptor agonist
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
FR2844273B1 (fr) 2002-09-05 2008-04-04 Aventis Pharma Sa Nouveaux composes heterocycliques, procede et intermediaires de preparation et utilisation comme medicament, notamment comme inhibiteurs de beta-lactamases et anti-bacteriens.
WO2004037971A2 (en) * 2002-10-25 2004-05-06 Pharmacia & Upjohn Company Llc Use of heterocyclic amine-type compounds as neuroprotective agents
JP2007500728A (ja) * 2003-07-31 2007-01-18 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｐｄｆインヒビターとしての二環式化合物および組成物
WO2005051488A1 (en) * 2003-11-26 2005-06-09 Pfizer Products Inc. Combination of dopamine agonists and monoamine reuptake inhibitors
BRPI0513846A (pt) 2004-08-13 2008-05-20 Boehringer Ingelheim Int formulação de comprimido de liberação prolongada contendo pramipexol ou um sal farmaceuticamente aceitável do mesmo, método para a fabricação do mesmo e o uso do mesmo
EP2431026A1 (en) 2004-08-13 2012-03-21 Boehringer Ingelheim International GmbH Extended release pellet formulation containing Pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
AR052227A1 (es) * 2004-11-05 2007-03-07 Wyeth Corp Metabolitos derivados de [1,4] diazepin [ 6,7,1-ij] quinolina, metodos de preparacion y usos de los mismos
GT200500317A (es) 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
CA2609562A1 (en) 2005-06-14 2006-12-28 Schering Corporation Macrocyclic heterocyclic aspartyl protease inhibitors
AR054849A1 (es) 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
US20140080813A1 (en) 2012-09-14 2014-03-20 AbbVie Deutschland GmbH & Co. KG Tricyclic quinoline and quinoxaline derivatives
CA2884548A1 (en) 2012-09-14 2014-03-20 AbbVie Deutschland GmbH & Co. KG Tricyclic quinoline and quinoxaline derivatives

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR900701260A (ko) * 1988-05-09 1990-12-01 로버트 에이. 아미테이지 2,3-디하이드로-1h-페날렌-2-아민 불안해소/우울증 방지제

Also Published As

Publication number Publication date
HU211702A9 (en) 1995-12-28
DE69016430D1 (de) 1995-03-09
WO1990015058A1 (en) 1990-12-13
FI96687B (fi) 1996-04-30
HU210264B (en) 1995-03-28
AU5743890A (en) 1991-01-07
AU626427B2 (en) 1992-07-30
JPH04506071A (ja) 1992-10-22
EP0480939A1 (en) 1992-04-22
FI96310C (fi) 1996-06-10
KR920701204A (ko) 1992-08-11
NO914827L (no) 1992-02-07
HU905216D0 (en) 1992-02-28
RU2023712C1 (ru) 1994-11-30
CA2051697A1 (en) 1990-12-10
DE69016430T2 (de) 1995-06-01
CA2051697C (en) 1996-10-08
NO914827D0 (no) 1991-12-06
FI944704A0 (fi) 1994-10-07
FI96687C (fi) 1996-08-12
FI96310B (fi) 1996-02-29
KR0167346B1 (ko) 1999-01-15
EP0480939B1 (en) 1995-01-25
HUT60269A (en) 1992-08-28
ATE117688T1 (de) 1995-02-15
FI944704A (fi) 1994-10-07
HK65397A (en) 1997-05-23
JP2955358B2 (ja) 1999-10-04
NO301421B1 (no) 1997-10-27
DK0480939T3 (da) 1995-07-10
FI915715A0 (fi) 1991-12-04

Similar Documents

Publication Publication Date Title
ES2067744T3 (es) Aminas heterociclicas con actividad sobre el sistema nervioso central.
FI102175B (fi) Menetelmä terapeuttisesti käyttökelpoisten piperatsiinijohdannaisten v almistamiseksi
DE3681517D1 (de) Thiazolidinderivate, verfahren zu deren herstellung und deren anwendung.
PE20001467A1 (es) Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquinina
MC2195A1 (fr) Derives d'acides amines
PE20040522A1 (es) Derivados de diarilurea dependientes de la cinasa de proteina
AR047557A1 (es) Compuestos derivados de piridazina y su uso como agentes terapeuticos
DK0632036T3 (da) Amidderivater med antipypercholesteræmisk aktivitet, deres fremstilling og deres terapeutiske anvendelser
NO910860D0 (no) Fremgangsmaate for fremstilling av azabicyklo- og azacyklo-oksiner og -aminer.
FR2581063B1 (fr) Amino-2 thiazoles n-substitues, leur procede de preparation et leur application en therapeutique
YU46706B (sh) Postupak za dobijanje amidnih jedinjenja
ATE101040T1 (de) Derivate und analoge von pyrimidon zur behandlung von asthma und bestimmte hautkrankheiten.
KR900012893A (ko) 치환된-아세트 아미드 화합물 및 그 제조방법
KR920701122A (ko) 신규 이환식 아미노-치환 화합물
DE69315363D1 (de) Amphotere tricyclische Verbindungen als antihistaminische und antiallergische Mittel
DK249288D0 (da) Substituerede silylalkylenaminer og farmaceutisk acceptable salte deraf, deres fremstilling og anvendelse
DE3778642D1 (de) Therapeutikum zur behandlung von magengeschwueren.
ATE250413T1 (de) 2-aminotetraline zur behandlung von glaukom
KR900003141A (ko) 신규한 벤즈아졸 유도체, 이의 제조방법과 이러한 화합물들을 함유하는 약학적 제제 및 이의 용도
KR920011491A (ko) 헥사히드로-8-히드록시-2, 6-메타노-2h-퀴놀리진-3(4h)-온 및 관련 화합물의 특정 에스테르를 함유하는 인식 장애 치료용 제약 조성물
ES8605265A1 (es) Procedimiento para la obtencion de la 8-(4-(4-(2-pirimidi- nil)-1-piperazinil)butil)-8-azaspiro(4,5)decano-7,9-diona y su clorhidrato
DE3772764D1 (de) Anwendung von n-((1-aethyl-2-pyrrolidinyl)methyl)-methoxy-5-sulfamoylbenzamid zur sterilitaetsbehandlung.
BRPI0417241A (pt) agente e processo para a prevenção e/ou para o tratamento de disfunção do cérebro superior, e, uso de um derivado de xantina, ou um sal farmaceuticamente aceitável do mesmo
DE69010606D1 (de) 3-Isoxazolonderivate, ihre Herstellung und ihre Anwendung in der Therapeutik.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 480939

Country of ref document: ES